FDA Grants Accelerated Approval to the Combination of Avutometinib and Defactinib for KRAS-mutated Recurrent Low-Grade Serous Ovarian Cancer By Ogkologos - May 30, 2025 568 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the RAMP-201 study Source RELATED ARTICLESMORE FROM AUTHOR Adding Epcoritamab to Lenalidomide and Rituximab Results in Higher Response Rate and Longer PFS in Patients with Relapsed or Refractory Follicular Lymphoma Patient Guide in Prostate Cancer Now Available in Vietnamese One Dose of Either a Bivalent or Nonavalent HPV Vaccine Provides Protection Against HPV16 or HPV18 Infection and Is Not Inferior To Two Doses MOST POPULAR What Do You Put In Your Pocket? April 28, 2021 EMA Recommends Extension of Therapeutic Indications for Tremelimumab July 20, 2023 EMA Recommends Extension of Therapeutic Indications for Cabozantinib April 29, 2022 FDA Grants Accelerated Approval to Sevabertinib for Non-Squamous NSCLC November 27, 2025 Load more HOT NEWS ESMO Welcomes the European Commission’s Life Sciences Strategy: A Vital Step... Thanks For Making This GivingTuesday Our Best One Yet! Cancer in My Community: Working Toward Early Diagnosis for Children With... Ventana HER2 Dual ISH Assay, A New Diagnostic Tool From Roche,...
